ERNA Ernexa Therapeutics Inc. Forecast, Technical & Fundamental Analysis
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs... Show more
ERNA is expected to report earnings to rise 70.16% to -210 cents per share on August 17
Q2'26
Est.
$-2.11
Q4'22
Missed
by $1.10
Q3'22
Missed
by $0.29
Q2'22
Beat
by $0.07
Q1'22
Beat
by $0.04
The last earnings report on March 20 showed earnings per share of -124 cents, missing the estimate of -14 cents. With 18.42K shares outstanding, the current market capitalization sits at 6.90M.
A.I. Advisor
published General Information
General Information
a developer of biomedical research products in the field of stem cells and regenerative medicine
A.I.dvisor indicates that over the last year, ERNA has been loosely correlated with MDGL. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ERNA jumps, then MDGL could also see price increases.
ERNA's Stochastic Oscillator stays in oversold zone for 14 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ERNA advanced for three days, in of 196 cases, the price rose further within the following month. The odds of a continued upward trend are .
ERNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for ERNA moved out of overbought territory on May 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 13 similar instances where the indicator moved out of overbought territory. In of the 13 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ERNA as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ERNA turned negative on May 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .
ERNA moved below its 50-day moving average on June 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ERNA crossed bearishly below the 50-day moving average on June 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ERNA entered a downward trend on June 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.007) is normal, around the industry mean (20.966). P/E Ratio (0.005) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). ERNA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (1250.000) is also within normal values, averaging (367.026).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ERNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
